| 000 | 01108 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250511175837.0 | ||
| 264 | 0 | _c19920408 | |
| 008 | 199204s 0 0 eng d | ||
| 022 | _a0003-4819 | ||
| 024 | 7 |
_a10.7326/0003-4819-116-7-604 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSalit, I E | |
| 245 | 0 | 0 |
_aWhy was treatment of cytomegalovirus retinitis randomized? _h[electronic resource] |
| 260 |
_bAnnals of internal medicine _cApr 1992 |
||
| 300 |
_a604-5 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xdrug therapy |
| 650 | 0 | 4 |
_aEye Infections, Viral _xdrug therapy |
| 650 | 0 | 4 | _aFoscarnet |
| 650 | 0 | 4 |
_aGanciclovir _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPhosphonoacetic Acid _xanalogs & derivatives |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aRetinitis _xdrug therapy |
| 773 | 0 |
_tAnnals of internal medicine _gvol. 116 _gno. 7 _gp. 604-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7326/0003-4819-116-7-604 _zAvailable from publisher's website |
| 999 |
_c1318431 _d1318431 |
||